285 results about "Intestinal inflammation" patented technology

The invention discloses an enteritis patient condition severity risk early warning method, a medium and equipment. The method comprises the following steps: acquiring a borborygmus original signal and a clinical multi-dimensional physiological parameter sequence through a sensing device; constructing a borborygmus dynamic characteristic spectrum based on the borborygmus original signal to generate an acoustic biomarker time sequence; inputting the acoustic biomarker time sequence and the clinical multi-dimensional physiological parameter sequence into a multi-modal fusion early warning model to obtain an intestinal inflammation risk index; executing a signal quality self-evaluation process and generating a data quality warning code when the signal quality is abnormal; triggering a multi-node collaborative monitoring mechanism based on the risk index to generate an intestinal state multi-dimensional situation map; establishing an individualized risk baseline and generating a graded early warning instruction; and finally outputting a comprehensive early warning report. According to the method, multi-modal fusion analysis of the borborygmus signal and the clinical parameters is realized, the accuracy and timeliness of illness state early warning are remarkably improved through dynamic risk assessment and signal quality monitoring, and a reliable basis is provided for clinical decision making.

The invention belongs to the technical field of microorganisms, and particularly relates to a lactobacillus paracasei strain and application thereof. The invention discloses a Lactobacillus paracasei strain, the name of the Lactobacillus paracasei strain is Lactobacillus paracasei WG-Lpc 63, the Lactobacillus paracasei strain is preserved in China General Microbiological Culture Collection Center on August 27th, 2024, and the preservation number is CGMCC No. 31768. The Lactobacillus paracasei strain is named as Lactobacillus paracasei WG-Lpc 63, and the Lactobacillus paracasei strain is named as Lactobacillus paracasei WG-Lpc 63. The strain disclosed by the invention has good acid production capacity, cholate tolerance and intestinal tract adhesion capacity, and has the effects of regulating intestinal flora balance and relieving intestinal inflammation.

The invention discloses a medicinal and edible homologous compound based on probiotic fermentation synergy and application of the medicinal and edible homologous compound in blood sugar regulation and control, and belongs to the technical field of microorganisms and fermentation engineering. The preparation method comprises the following steps: respectively carrying out two-stage fermentation on aloe, mulberry leaves and liquorice by utilizing saccharomyces cerevisiae BLCC4-0032 and plant lactobacillus DFR-1, so as to obtain a fermentation mixture; the preparation method comprises the following steps: fermenting a fermentation mixture, adding balsam pear peptide into the fermentation mixture to obtain a medicinal and edible compound, forming a metabolic closed loop, and cooperatively regulating a'blood sugar-liver-intestinal flora axis', thereby providing a new solution for diabetes intervention, and opening up a new path for preventing non-alcoholic fatty liver and intestinal inflammation caused by glucose and lipid metabolism disorder.

The invention relates to the technical field of functional food and biological medicine, in particular to a modified pseudo-ginseng exosome and an intestinal conditioning gel composition and application thereof. According to the gel beverage, an exosome derived from panax notoginseng callus cultured in a laboratory is used as a core active component, is modified through phosphatidylserine-aminated pectin-genipin and is embedded into a hydrogel matrix composed of carboxymethyl chitosan and sodium alginate, so that the exosome is protected from being degraded in the stomach, and the activity of the exosome in the stomach is improved. The exosome can be effectively released under the intestinal pH and flora environment, so that the targeted delivery of the intestinal tract is realized, and the preparation method is suitable for improving the intestinal inflammation and maintaining the intestinal health. The invention can effectively solve the technical problems of uncontrollable raw material quality and safety, low oral delivery stability and active ingredient availability and poor medication compliance of the existing plant exosome.

The invention discloses a personalized diet recommendation method for enteritis patients, a medium and equipment. The method comprises the following steps: continuously collecting diet image data, physiological state time sequence data and subjective symptom feedback data; performing food material component deconstruction and cooking mode identification on the diet image through a convolutional neural network, and generating a structured diet vector; analyzing physiological state time sequence data by using a hidden Markov model, and constructing an individualized physiological rhythm map; establishing a symptom triggering condition probability matrix based on a multi-modal association mining algorithm; generating an exploratory diet scheme according to the real-time physiological state of the user and the conditional probability matrix; dynamically updating the conditional probability matrix through an online reinforcement learning mechanism; and finally, periodically outputting a personalized diet taboo list and a safety exploration list. According to the method, through the dynamic correlation analysis of fusing the time sequence physiological features and the dietary components, accurate matching of diet recommendation and individual intestinal tract state fluctuation is realized, and the individuation and adaptability of diet intervention are effectively improved.

The invention relates to the technical field of functional food, in particular to immune regulation type prebiotic syrup with synergy of galactomannan. The active components of the composite solid beverage are prepared from the following raw materials in percentage by weight: 20%-35% of fructo-oligosaccharide, 10%-18% of galactooligosaccharide, 8%-15% of stachyose, 3%-7% of xylooligosaccharide, 5%-12% of lactitol, 5%-10% of galactomannan, 2%-5% of yeast beta-glucan and 1%-3% of N-acetylglucosamine. The composition further comprises 4-8% of inulin and 3-6% of resistant dextrin as a matrix filling and slow-release carrier, and the sum of the weight percentages of all the active ingredients and the carrier is 100%. By remodeling intestinal microecology and inhibiting inflammation pathways, the intestinal inflammation state can be remarkably improved, expression of intestinal mucosa tight junction protein is promoted, and an innovative solution is provided for people suffering from chronic bowel diseases and immune imbalance.

The invention belongs to the related technical field of pet prescription food products, and particularly relates to a prescription food for pet dogs with acute intestinal inflammation and a preparation method of the prescription food, the prescription food comprises various components such as rice, barley, chicken powder and corn protein powder, and probiotics are self-made and comprise bifidobacterium, lactobacillus acidophilus and lactobacillus casei. The preparation method comprises the steps of quantitative raw material weighing, auxiliary agent grinding, constant-temperature accurate grinding, adding of specific components for accurate grinding again, heat preservation, deodorization and degassing, drop casting forming, cooling, packaging, sealed storage and the like. Compared with the prior art, the prescription food is high in safety, and feeding tests of healthy dogs have no abnormity; clinical cases show that the leucocyte number and the inflammatory factor content of sick dogs can be reduced; the intestinal barrier can be repaired, so that the intestinal mucosa repair is accelerated; intestinal flora can be improved, and the content of short-chain fatty acid in excrement is increased; the nutrition state can be maintained, and the weight loss range of sick dogs is reduced.

The invention discloses lactobacillus paracasei CFCFC018, a microbial agent and application of the lactobacillus paracasei CFCFC018, and belongs to the technical field of microorganisms. The lactobacillus paracasei CFCFC018 is separated from intestinal contents of rural cats in half-farming and half-pastoral areas in Inner Mongolia, does not need genetic engineering modification, can highly express amino acids and neurotransmitters, can remarkably relieve mammary gland alveolar structure damage in mammary gland tissues of rats suffering from mastitis induced by staphylococcus aureus, and has the advantages of being high in safety and good in stability. The thickening of a mammary gland interacellular matrix layer is avoided, the infiltration number of neutrophils is reduced, the damage degree of mammary gland tissues is reduced, and a certain protection effect on the mammary gland tissues is achieved. The research also shows that the strain can reduce the abundance of harmful bacteria in excrement, improve intestinal inflammation and relieve edema of intestinal submucosa, which provides a new thought for preventing and treating mastitis by regulating intestinal microbiota.

The invention discloses a lactobacillus mucus fermentation strain. The microbial preservation number of the lactobacillus mucus fermentation strain is CCTCC (China Center for Type Culture Collection) NO: M 20252262. The strain can inhibit enterotoxigenic escherichia coli, and can treat or slow down diarrhea, intestinal oxidative damage, intestinal inflammation damage, intestinal morphological damage, intestinal barrier function damage and intestinal flora disorder caused by the enterotoxigenic escherichia coli. The strain is a probiotic with a clinical application prospect.

The invention discloses a microsphere entrapped with probiotics and ginsenoside as well as a preparation method and application of the microsphere, and aims to realize efficient treatment of flora imbalance inflammatory bowel disease (IBD). The microspheres adopt a bi-component synergistic entrapment technology, can stably bear probiotics and ginsenoside, effectively avoid inactivation or degradation of the probiotics and ginsenoside in gastric acid and cholate environments, and ensure directional release and efficient utilization of the probiotics and ginsenoside in intestinal tracts. The microspheres not only provide a protection effect as a delivery carrier, but also construct a'microreactor 'system, and provide a suitable microenvironment for survival of probiotics and conversion of ginsenoside. Probiotics secrete a specific enzyme to promote prototype ginsenoside to be converted into rare ginsenoside with higher activity and stronger solubility while regulating intestinal flora balance and relieving intestinal inflammation, so that the bioavailability and efficacy of the rare ginsenoside are remarkably improved. According to the microsphere system, the technical bottlenecks of the existing treatment means in the aspects of activity maintenance, directional release and conversion utilization are broken through by realizing the synergistic effect of the probiotics and the ginsenoside, and a brand-new strategy and a technical platform are provided for treatment of flora imbalance related diseases such as IBD.

The invention relates to the technical field of microorganisms, and particularly discloses bifidobacterium longum LFS01 and application thereof. The bifidobacterium longum LFS01 is preserved in the China General Microbiological Culture Collection Center on July 9, 2025, the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.35159, and the bifidobacterium longum LFS01 is classified and named as the bifidobacterium longum LFS01. The bifidobacterium longum LFS01 provided by the invention can be specifically and efficiently colonized in an intestinal tract after gut cleaning, proliferation of pathogenic bacteria is inhibited through competitive rejection, an intestinal barrier is repaired in a multi-target manner, intestinal inflammation can be effectively relieved, a flora structure can be improved, mucous membrane integrity can be recovered, and the intestinal tract can be effectively protected. A safe and effective biological prevention and treatment strategy is provided for solving the problems of flora disorder and pathogenic bacterium infection caused by gut purging.

The invention discloses a full-life-cycle health management method for enteritis patients, a medium and equipment, and the method comprises the steps: extracting a key lever factor through a lever point recognition algorithm based on obtained full-life-cycle health data, and generating a lever point intervention priority sequence; generating an individualized toughness development path plan in combination with a calculation result of the toughness evaluation model, and designing a structured self-verification experiment scheme according to the individualized toughness development path plan; continuously updating the leverage point recognition algorithm and the toughness evaluation model by using an adaptive learning algorithm according to a scheme execution result until the optimal parameter configuration and the individualized health management strategy are locked; and when the sorting stability of the key lever factors exceeds the standard, starting a grading response mechanism to generate a precise intervention scheme, and finally outputting a full-life-cycle health management comprehensive scheme. According to the method, a dynamic optimization closed loop is constructed, so that a management strategy is converted from static matching to dynamic self-adaption, and the defects of an existing method in the aspects of intervention target spot recognition, adaptive capacity quantification and strategy continuous optimization are overcome.

The invention relates to lactobacillus plantarum-derived inorganic polyphosphate and application thereof in promoting cell proliferation. The preparation method of the lactobacillus plantarum-derived inorganic polyphosphate comprises the following step: extracting from lactobacillus plantarum by using glass milk. According to the invention, long-chain PolyP (PolyPLp) with the chain length of about 250 phosphate residues is extracted and purified from lactobacillus plantarum by using glass milk. And the effect of promoting cell proliferation is proved. An IL-1beta-induced Caco-2 intestinal epithelial cell barrier injury model is utilized, it is found that PolyP has the function of relieving intestinal inflammation, the effect of PolyP has chain length dependence, and the action effect of PolyPLp is optimal.

According to the present invention, a method for producing a hot water extract of an aboveground portion of a plant of the genus aralia is characterized by comprising a step for adding sodium hydrogen carbonate.

The application discloses a feed additive for improving intestinal health of animals and preventing and treating intestinal diseases and application thereof, and relates to the technical field of green and healthy breeding. The application firstly confirms that indole-3-butyric acid (IBA) has no toxic effect on cells and can relieve oxidative stress damage and inflammation damage of the cells in an effective concentration. Meanwhile, the application also fills the application blank of IBA as one of indole derivatives in livestock production, and provides experimental basis and theoretical basis for the fact that IBA is expected to be a new green additive for replacing antibiotics and zinc oxide. More importantly, the application also finds that IBA has positive effects in aspects of resisting diarrhea, repairing intestinal barrier damage, relieving intestinal inflammation and preventing and treating intestinal related diseases.

The invention discloses a multifunctional probiotic engineering bacterium capable of continuously producing melanin in situ in vivo and application of the multifunctional probiotic engineering bacterium. According to the application, a genetically engineered bacterium EcN-Mel is constructed by adopting a probiotic Escherichia coli 1917 (EcN), and the EcN-Mel has the advantages of oral safety, continuous in-situ melanin production, inflammation site targeting and multi-mechanism synergistic treatment of acute radiation enteritis; researches find that EcN-Mel has a better curative effect on acute radiation enteritis than EcN; compared with the traditional Chinese medicine composition, the traditional Chinese medicine composition has stronger free radical scavenging capability, stronger capability of reducing inflammation level, stronger capability of increasing intestinal beneficial flora and reducing harmful flora, stronger capability of targeting a focus part-intestinal inflammation part, higher survival rate in a stomach acidic environment, longer retention time in the intestinal inflammation part, concentration increased by about 3 times, and more stable in vivo.

The invention belongs to the technical field of biological medicines, and particularly relates to a multifunctional peptide and application thereof in anti-inflammatory, antibacterial, mucous membrane repair and intestinal secretion promotion. Specifically, the invention designs a polypeptide and an analogue which have guanylate cyclase C receptor (GUCY2C) agonist activity and anti-inflammatory, antibacterial and mucous membrane repair functions at the same time. The polypeptide can be combined with GUCY2C, stimulate generation of cyclic guanosine monophosphate (cGMP) in cells, promote intestinal fluid secretion, inhibit release of proinflammatory factors, relieve inflammatory response, promote repair of intestinal injury mucosa, inhibit growth of opportunistic pathogenic bacteria and accelerate intestinal homeostasis recovery after intestinal preparation. The composition can effectively promote intestinal tract cleaning, does not cause intestinal inflammation and mucosal lesion, has no hemolytic toxicity and cytotoxicity, is high in safety, and has a good clinical application prospect.

The invention provides a method for regulating and controlling proliferation and movement of human peripheral blood T cells by Amuc1100 protein. The method relates to the technologies of separation, activation and culture of human peripheral blood T cells, CCK-8 cell proliferation detection, Transwell cell chemotactic detection, flow cytometry receptor expression body detection and the like. The application of the Amuc1100 protein to treat T cells proves that the protein can significantly down-regulate the expression of CD25 and CXCR4 of the T cells and inhibit T cell proliferation and CXCL12 induced T cell chemotactic movement respectively. The method and research means for in-vitro regulation of T cell proliferation and chemotactic movement can be applied to targeted regulation of T cells and directional migration of intestinal tracts of the T cells, and are used for maintaining the steady state of the intestinal tracts, relieving intestinal inflammations and screening drugs to treat diseases related to the intestinal inflammations.

The invention discloses multifunctional selenium nanoparticles for treating inflammatory bowel diseases as well as a preparation method and application of the multifunctional selenium nanoparticles, and relates to the technical field of biological medicines. The multifunctional selenium nanoparticle is of a core-shell structure and comprises an inner core and an outer layer coating the inner core, the inner core is selenium nanoparticles; and the outer layer is a polydopamine shell embedded with chitosan oligosaccharide. The multifunctional selenium nanoparticles provided by the invention have good stability and dispersibility, can target intestinal inflammation parts, prolong the in-vivo time of the nanoparticles, and show strong antioxidant and anti-inflammatory activity on cell and animal levels. The whole nanoparticle is based on low toxicity and colon targeting of a natural material, is higher in safety compared with a traditional glucocorticoid / biological preparation, relieves intestinal inflammation by adjusting a redox steady state, prolonging drug action time and the like, and is expected to become a novel colitis treatment strategy with high efficiency, targeting property and safety.

The application provides a copper selenide-halloysite-mannose composite drug delivery system, which comprises a carrier, the carrier is halloysite nanotubes (HNTs), copper selenide nanoparticles (CuSe) are in situ grown on the tube wall of the halloysite nanotubes to form a composite CuSe@HNTs; and mannose is loaded in the lumen of the CuSe@HNTs to form a composite drug delivery system CuSe@HNTs@ME. The application also provides a preparation method and application of the copper selenide-halloysite-mannose composite drug delivery system. The drug delivery system can maintain stability in a gastric acid environment, directly reaches an intestinal inflammation site through an oral route, and significantly reduces intestinal inflammation symptoms.

The invention discloses a copper ion-kaempferol nano-composite and application thereof in treatment of inflammatory bowel disease, the obtained nano-composite has very strong stability and active oxygen scavenging ability, and has excellent oxidation resistance and anti-inflammatory ability, and the specific performance is as follows: the surface is negatively charged, and the nano-composite can specifically target the diseased region of intestinal inflammation, so that the copper ion-kaempferol nano-composite can be applied to treatment of inflammatory bowel disease. The intestinal mucosal barrier injury is effectively repaired, the imbalance state of intestinal flora is adjusted, and the intestinal inflammation microenvironment is remarkably improved; the antioxidant and anti-inflammatory capacities of cells can be enhanced by regulating and controlling a PI3K-Akt signal channel and a nuclear factor kappa B (NF-kappa B) signal channel; the compound shows an excellent treatment effect in mouse models of typical inflammatory bowel diseases such as ulcerative colitis and Crohn's disease and related complications of bowel diseases. The invention provides a new way for constructing a multi-target and multi-layer treatment platform for the inflammatory bowel disease of a natural product.

This invention belongs to the field of vertebrate technology, specifically relating to a method for constructing a complex inflammatory animal model in middle-aged and elderly individuals and its related applications. The method includes: selecting adult animals for adaptive feeding, daily subcutaneous injection of D-galactose to establish a susceptibility to aging and oxidative stress, and administering sodium dextran sulfate (DSS) solution within a specific time window to induce intestinal inflammation, forming a complex inflammatory state through gut-hepatic axis interactions. The constructed animal model simultaneously exhibits intestinal inflammatory damage, abnormal hepatic oxidative stress, and aging-related characteristics, realistically simulating the pathological process of gut-hepatic axis dysfunction in middle-aged and elderly individuals. This model is suitable for screening and evaluating drugs, medical nutrition products, and functional foods that improve gut-hepatic axis dysfunction, providing a reliable technical platform for research on related disease mechanisms and the development of interventional substances.

The invention discloses application of loganin and / or hydroxygenkwanin in preparation of an EGFR (epidermal growth factor receptor) inhibitor for treating inflammatory bowel diseases. Molecular docking experiments find that loganin and hydroxygenkwanin can be specifically bound with EGFR protein, the binding energy is lower than-5kcal / mol, and the loganin and hydroxygenkwanin can inhibit EGFR protein expression, block downstream RAS / ERK signal channels, relieve intestinal inflammation and repair mucosal barriers. Animal experiments show that in a DSS-induced UC mouse model, the pathological manifestation of a mouse can be remarkably improved by administration of loganin, and the effect of a 100mg / kg dose group is remarkably superior to that of a positive drug control. The two natural small molecule compounds are used for preparing the EGFR inhibitor for treating the inflammatory bowel disease for the first time, a low-toxicity and high-efficiency brand-new scheme is provided for IBD treatment, the problems of drug resistance and toxic and side effects of existing drugs are hopefully solved, and wide clinical application prospects are achieved.

The present invention relates to a strain of Lactobacillus johnsonii N5 and its application in preventing and treating enteritis and diarrhea. Lactobacillus johnsonii N5), was deposited in the China Center for Type Culture Collection on February 10, 2023, with the deposit number CCTCC NO: M2023104. The Lactobacillus johnsonii N5 was isolated from the fecal microorganisms of piglets resistant to heat stress-induced diarrhea. This Lactobacillus johnsonii N5 has the effect of alleviating enteritis and diarrhea, which is specifically reflected in: significantly enhancing the expression of intestinal epithelial tight junction proteins and cytoprotective heat shock protein 70, improving the immune balance of animal intestinal T cells, enhancing immune tolerance, and reducing the degree of intestinal inflammation and the occurrence of diarrheal diseases in animals. Therefore, Lactobacillus johnsonii N5 has a significant effect in preventing and treating diarrhea and related intestinal inflammatory diseases.

The invention discloses application of rosmarinic acid in preparation of a medicine or health food for preventing and treating hyperuricemia of a patient with renal insufficiency. The medicine for preventing and treating hyperuricemia of the patient with renal insufficiency is an XOD inhibitor or an ABCG2 gene expression promoter. The rosmarinic acid can significantly reduce the serum uric acid level of HUA mice induced by high purine diet, promote ABCG2-mediated intestinal uric acid excretion, and relieve HUA-induced intestinal inflammation and barrier injury by adjusting intestinal flora. The rosmarinic acid is safe and free of toxic and side effects, and has very important application prospects.

A pharmaceutical composition includes a combination of a guanylate cyclase C (GUCY2C) agonist and a short-chain C2 to C5 fatty acid and / or a salt and / or a prodrug thereof in a therapeutically effective amount and one or more pharmaceutically acceptable excipients as well as to a method of preventing and / or treating colorectal tumorigenesis and / or carcinogenesis and / or chronic intestinal inflammation and / or cystic fibrosis related gastrointestinal manifestations by administering to a patient, who has developed or is at risk to develop colorectal tumorigenesis and / or carcinogenesis and / or chronic intestinal inflammation and / or cystic fibrosis related gastrointestinal manifestations, a therapeutically effective amount of a combination of a GUCY2C agonist and a short-chain C2 to C5 fatty acid or a salt or a prodrug thereof.

An engineered bacterium based on Bacillus subtilis is provided, a genome of the engineered bacterium includes a multi-enzyme element, and the multi-enzyme element comprises a class I β-agarase element (E1 element), a class II β-agarase element (E2 element), and an α-neoagaro-diohydrolase element (E3 element). The engineered bacterium integrates agarase genes into the Bacillus subtilis genome, achieving cascade catalysis of agarose to produce active oligosaccharides and monosaccharides, thereby utilizing the biological activity of these active oligosaccharides and monosaccharides to treat intestinal inflammation. An engineered biofilm based on Bacillus subtilis is also provided, which includes the engineered bacterium and its secretions. Furthermore, a living material for multi-enzyme display and treatment of intestinal inflammation in mice is also provided, which includes the engineered bacterium or the engineered biofilm.

The invention relates to a compound feed for promoting growth and development of meat pigeons. The compound feed comprises the following raw material components: corn flour, wheat flour, vegetable oil, an auxiliary agent and a beef tallow modified additive, wherein the beef tallow modified additive is a product obtained by blending beef tallow and amino acid, then carrying out ultrasonic heating on the blended beef tallow and amino acid and diatomite, and then carrying out a reaction. The beef tallow contains a large amount of fatty acid and can react with surface active hydroxyl groups of the diatomite after being mixed with the amino acid, the beef tallow and the amino acid can be loaded by the abundant porous structure of the diatomite, and the beef tallow, the amino acid and the beef tallow form a stable compound, so that harmful substances such as mould, bacteria and excessive ammonia gas are adsorbed by the diatomite; according to the method, the intestinal burden of the meat pigeons and the risk of intestinal inflammation are relieved, more nutrients and active substances are provided, and the absorption effect on corn flour and wheat flour is promoted, so that the absorption efficiency is improved, and the requirement of tissue protein synthesis is more accurately met.

The invention discloses an application of a P4HA1 inhibitor in preparation of a medicine for treating congenital megacolon-related enterocolitis, deeply clarifies an immune metabolic axis of 'P4HA1-hydroxyproline-eIF5A-IRF4-IL17', and discloses a new mechanism that metabolite hydroxyproline regulates the activity of eIF5A and promotes nuclear translocation of IRF4 so as to enhance TH17 cell mediated inflammatory response. Therefore, a brand new perspective is provided for understanding metabolic immune regulation of intestinal inflammation. By using the P4HA1 inhibitor (such as 1, 4-DPCA), secretion of IL-17 can be effectively inhibited, intestinal inflammation injury of HAEC model mice can be remarkably relieved, and a clear pharmacodynamic basis is achieved.

The invention provides an application of a heat shock protein 90 inhibitor in preparation of a medicine for treating intestinal injury and complicated intestinal inflammation thereof. The HSP90 inhibitor is suitable for treating colon tissue injury caused by a medicine for inducing Gasdermin E (GSDME) mediated pyroptosis. The HSP90 inhibitor specifically inhibits the expression of GSDME protein in normal intestinal epithelial cells and reduces the sensitivity of the normal intestinal epithelial cells to drug-induced GSDME-mediated pyroptosis, so that the damage to colon tissues is relieved, and the induced inflammatory response of the colon tissues is effectively inhibited. TAS-116 and BIIB021 are used as representative drugs of the HSP90 inhibitor, 4 mg / kg of TAS-116 and BIIB021 are used for a mouse colon injury model constructed by 5-FU and CDDP, and the result shows that the HSP90 inhibitor can obviously improve weight loss and colon tissue injury of mice caused by the drugs, and has a good application prospect. Therefore, the HSP90 inhibitor has remarkable curative effect and application value in the aspect of relieving or preventing and treating intestinal injury caused by drugs.